It achieves 90–95% control of tumor growth at 5–10 years and 40–80% normalization of hormonal hypersecretion at 5 years in patients with prolactin-, GH-, and ACTH-secreting adenomas [24]. This evidence concerns the gene POMC and neoplasm.